Hence, the differential cell survival observed between ALK+ and ALK- cell lines upon combination drug treatment is dependent on ERBB and ALK activities which are critical only in the EML4-ALK-driven NSCLC cell lines. The gene discussed is ALK; the disease is non-small cell lung carcinoma.